FDA warned 24hreup.biz for selling unapproved semaglutide drugs online to U.S. consumers without prescriptions.
What happened
FDA reviewed the website www.24hreup.biz and found semaglutide products marketed as 'Ozempic 0.5mg,' 'Ozempic 1mg,' and 'Rybelsus Semaglutide 14mg' offered for sale to U.S. consumers. FDA said there are no approved applications for the products offered and they were sold without a prescription. The letter says the products are therefore unapproved and misbranded (unlawfully labeled) drugs.
What FDA found
The website offered semaglutide drugs that do not have FDA-approved applications for the products being sold.
sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d), 355(a)]The website offered prescription semaglutide drugs for sale without requiring a prescription.
sections 503(b)(1) and 301(k) of the FD&C Act [21 U.S.C. §§ 353(b)(1), 331(k)]The labeling for the semaglutide drugs did not give adequate directions for a layperson to use them safely.
section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]The website caused unlawfully labeled drugs to be introduced into interstate commerce.
section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with the steps taken to correct the violations and prevent them from recurring. If corrections cannot be completed in that time, the company must state why and give a completion date.
Who should pay attention
- online sellers of prescription drugs to U.S. consumers
- companies distributing or reselling semaglutide products
- importers and websites offering foreign-labeled medicines
This is a summary. Read the original letter on fda.gov.